• 1. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 2. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 3. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 4. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 5. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers Phenol ethers
• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers

Professional Introduction to 2-(3-Ethoxyphenoxy)-N-methylethanamine (CAS No. 915921-56-1)

2-(3-Ethoxyphenoxy)-N-methylethanamine, a compound with the chemical identifier CAS No. 915921-56-1, represents a significant area of interest in the field of pharmaceutical chemistry and medicinal research. This compound, characterized by its unique structural and functional attributes, has garnered attention for its potential applications in the development of novel therapeutic agents. The molecular structure of this amine derivative incorporates an ethoxyphenyl moiety and a methyl-substituted ethylamine group, which together contribute to its distinct chemical properties and reactivity.

The ethoxyphenyl group, a key structural feature of 2-(3-Ethoxyphenoxy)-N-methylethanamine, is known for its ability to interact with various biological targets, making it a valuable component in the design of bioactive molecules. This moiety is often found in pharmacophores that exhibit significant affinity for enzymes and receptors involved in critical physiological pathways. The presence of the ethoxy group enhances the lipophilicity of the molecule, facilitating its penetration across biological membranes, which is a crucial factor in drug delivery systems.

In recent years, there has been a surge in research focused on developing small molecule inhibitors that target enzymes implicated in inflammatory and metabolic disorders. The structural framework of 2-(3-Ethoxyphenoxy)-N-methylethanamine aligns well with this objective, as it provides a scaffold for modulating the activity of enzymes such as cyclooxygenases (COX) and lipoxygenases (LOX). These enzymes are pivotal in the biosynthesis of pro-inflammatory mediators, making them prime targets for therapeutic intervention.

One of the most compelling aspects of this compound is its potential role in addressing neurological disorders. Emerging research indicates that amine derivatives with similar structural motifs may exert neuroprotective effects by inhibiting the activity of enzymes associated with neurodegenerative diseases. For instance, studies have suggested that compounds containing ethoxyphenyl groups can modulate the activity of acetylcholinesterase, an enzyme crucial for maintaining cognitive function. The methyl-substituted ethylamine group in 2-(3-Ethoxyphenoxy)-N-methylethanamine further enhances its interaction with biological targets, potentially leading to improved efficacy in treating conditions such as Alzheimer's disease.

The synthesis and characterization of 2-(3-Ethoxyphenoxy)-N-methylethanamine have been subjects of extensive investigation due to its promising pharmacological profile. Advanced synthetic methodologies have been employed to optimize yield and purity, ensuring that the compound meets stringent quality standards required for preclinical and clinical studies. Techniques such as palladium-catalyzed cross-coupling reactions and nucleophilic substitution have been particularly useful in constructing the desired molecular framework.

The pharmacokinetic properties of this compound are also under scrutiny to ensure its suitability for therapeutic applications. Studies have focused on evaluating its solubility, stability, and metabolic pathways to predict its behavior within biological systems. The ethoxyphenyl group's contribution to lipophilicity is balanced by the polar nature of the amine functionality, which influences its distribution and excretion rates. These factors are critical in determining the optimal dosing regimen and formulation strategies.

In conclusion, 2-(3-Ethoxyphenoxy)-N-methylethanamine (CAS No. 915921-56-1) stands out as a promising candidate for further exploration in pharmaceutical research. Its unique structural features offer a versatile platform for designing molecules with potential therapeutic benefits across multiple disease areas. As research continues to uncover new applications for this compound, it is likely to play an increasingly significant role in the development of next-generation drugs aimed at addressing unmet medical needs.

• 13468-02-5(N,N-Dimethyl-2-phenoxyethanamine)
• 54063-24-0(Ethanamine,2-(3,5-diethoxyphenoxy)-N,N-diethyl-)
• 37421-04-8(N-Methyl-2-phenoxyethanamine)
• 91251-54-6(N-Ethyl-2-phenoxyethanamine)
• 6487-86-1(2-(3-Methoxyphenoxy)ethanamine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)